TMDX LEGAL NEWS: A Class Action was filed on behalf of TransMedics Group, Inc. Investors for Fraud - Contact BFA Law if You Suffered Losses

Core Viewpoint - A lawsuit has been filed against TransMedics Group, Inc. and certain senior executives for potential violations of federal securities laws, alleging misrepresentation and fraudulent practices [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Massachusetts, captioned Jewik v. TransMedics Group, Inc. et al, No. 25-cv-10385 [2]. - Investors have until April 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - TransMedics is a commercial-stage medical technology company known for its "Organ Care System" (OCS), which maintains donor organs' viability before transplant [3]. Group 3: Allegations - The complaint alleges that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics, misrepresented safety practices, and lacked proper safety oversight [4]. - Specific accusations include overcharging for OCS and misappropriating corporate resources, leading to a stock price decline of approximately 4% from $86.99 to$83.14 between February 21 and February 23, 2024 [5]. Group 4: Stock Performance and Impact - Following the resignation of the CFO and a narrowed financial outlook in December 2024, a report by Scorpion Capital in January 2025 claimed that TransMedics' growth was driven by anti-competitive schemes and billing fraud, resulting in a further 5% decline in stock price from $72.55 to$68.81 between January 8 and January 10, 2025 [6].